The U.S. Food and Drug Administration (FDA) has adopted a policy of enforcement discretion that permits compounding pharmacies to immediately produce six previously restricted peptides—BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500—without awaiting formal rulemaking, according to an Oct. 28 NBC News report by Berkeley Lovelace Jr. The move, which bypasses the usual process of proposed regulations, public comments, and final rulemaking, is intended to improve patient safety by shifting consumers away from unregulated research-use-only products. Pharmacies that compound these peptides must certify their identity and purity and report adverse effects, adding safeguards to the supply chain.
The decision has significant implications for the peptide therapy sector, including Adaptogenics Health Corp., a science-led company focused on identifying, acquiring, designing, and advancing proprietary peptide and small molecule programs. Adaptogenics (CSE: ADPT) is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology, and inflammation, and is developing delivery technologies to improve the performance of promising molecules. The company also continues its nutraceutical operations while assessing GLP-1 companion products aimed at addressing challenges associated with medical weight loss, such as muscle loss, nutritional deficiencies, and reduced physical function.
While Health and Human Services officials argue that the approach could enhance patient safety, critics such as the Center for Science in the Public Interest and the Partnership for Safe Medicines warn that the substances lack sufficient evidence of safety and effectiveness. This regulatory shift highlights the evolving landscape for peptide therapies and could create new opportunities for companies operating in the space. For investors, the latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT.
The announcement was disseminated by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio within IBN, which provides wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The policy change could accelerate the availability of peptide therapies, but questions about safety and efficacy remain, making it a development worth watching for industry stakeholders and patients alike.
